AKT1 and colorectal carcinoma: Taken together, our results on the combination treatment, which showed synergistic effects between KY1022 and an AKT inhibitor, demonstrate a significantly higher clinical efficacy than either agent alone in metastatic CRC patients, accompanied with improvements for a worse/poorer prognosis.